Multiple coupling of neurohormone receptors with cyclic AMP and inositol phosphate production in anterior pituitary cells.
Regulation of adenohypophyseal hormone secretions has been shown to involve cyclic AMP production, modulation of phosphatidyl inositol diphosphate breakdown and Ca2+ mobilization. Various neurohormone receptors are positively or negatively coupled to adenylate cyclase activity in anterior pituitary cells. The effects of these neurohormones on adenylate cyclase activity are consistent with the effect on hormone secretions, suggesting that modulation of the enzyme activity is actually involved in the regulation of adenohypophyseal secretions. Thus DA inhibits, whereas VIP stimulates adenylate cyclase activity of the same cell type, which, according to the effect of these neurohormones on prolactin secretion, appear to be lactotrophs. On the other hand, SRIF inhibits, whereas GRF stimulates the adenylate cyclase activity of another cell type, namely somatotrophs, whereas CRF appears to act on a third cell type, corticotrophs. Peripheral hormones have been shown to modulate the sensitivity of anterior pituitary cells to these neurohormones. Estradiol long-term treatment has an anti-dopaminergic effect on prolactin secretion. The steroid also suppresses the dopamine inhibition of adenylate cyclase. This effect appears selective to the DA inhibition, since AII inhibition of the enzyme is only partially reduced, whereas the somatostatin inhibition is markedly increased. Peripheral hormones seem to affect the sensitivity of adenohypophyseal cells not only by modulating the number of receptors for a given neurohormone but also by interfering with the coupling mechanisms of these receptors. AII and DA inhibit the adenylate cyclase activity of lactotroph cells. The prolactin stimulation induced by angiotensin is not consistent with the effect of the peptide on adenylate cyclase.(ABSTRACT TRUNCATED AT 250 WORDS)
Enjalbert
A
A
INSERM U159, Neuroendocrinologie, Centre Paul-Broca, Paris, France.
Bertrand
P
P
Bockaert
J
J
Drouva
S
S
Kordon
C
C
D037361:Adenylate Cyclase Toxin; D000067956:Adenylyl Cyclase Inhibitors; D000262:Adenylyl Cyclases / Q000378:metabolism; D000804:Angiotensin II / Q000494:pharmacology*; D000818:Animals; D000242:Cyclic AMP / Q000378:metabolism*; D004298:Dopamine / Q000494:pharmacology*; D004789:Enzyme Activation; D004958:Estradiol / Q000494:pharmacology; D004967:Estrogens / Q000494:pharmacology; D007295:Inositol Phosphates / Q000096:biosynthesis*; D010903:Pituitary Gland, Anterior / Q000201:enzymology / Q000378:metabolism*; D011388:Prolactin / Q000378:metabolism; D011954:Receptors, Dopamine / Q000378:metabolism; D011979:Receptors, Pituitary Hormone / Q000378:metabolism*; D013403:Sugar Phosphates / Q000096:biosynthesis*; D010566:Virulence Factors, Bordetella
D037361:Adenylate Cyclase Toxin; D000067956:Adenylyl Cyclase Inhibitors; D004967:Estrogens; D007295:Inositol Phosphates; D011954:Receptors, Dopamine; D011979:Receptors, Pituitary Hormone; D013403:Sugar Phosphates; D010566:Virulence Factors, Bordetella; D000804:Angiotensin II; D004958:Estradiol; D011388:Prolactin; D000242:Cyclic AMP; D000262:Adenylyl Cyclases; D004298:Dopamine